Recent Articles
Dealmakers weekly review – February 20 2012 – Biogen Idec, Stromedix, Tetraphase, BioGaia, Nexmed, Swedish Orphan Biovitrum
February 21, 2012 : dealtalk
Partnering was up on the previous week in terms of number of deals, but no deals of financial significance were announced. Partnering in terms of big headline deals seems to have taken breather for the past few weeks. more »
Cultural Pitfalls in International Business Development and Licensing. Part 4: Some Tricky Asian Name Conventions
February 20, 2012 : best practice, business development, licensing, partnering
By Dr. Norbert Rau, RauCon Business Development.
Part 1 of this article dealt about the conflicts arising from the value and use of time in different cultures. Part 2 looked into how affirmative or negative answers can be misunderstood. Part 3 looked into the use of names in Europe which can be very confusing, while the present part points out a few peculiarities of Asian names. more »
Biopharmaceuticals: The 2011 Health Care Value Creators Report
February 14, 2012 : BCG, insight, value creation
The 2011 Health Care Value Creators: How can healthcare companies create more value?
February 14, 2012 : annual reports, BCG, insight
The 2011 Healthcare Value Creators Report. Written by Michael Ringel, Colm Foley and Olivier Wierzba for Boston Consulting Group (BCG).
Strength in the Storm: How Biopharmaceutical and Medical Technology Companies Can Create Value in a Challenging Business Environment builds on the thirteenth annual report in the Value Creators series published by The Boston Consulting Group (BCG). more »
Dealmakers weekly review – February 13 2012 – Eli Lilly, Roche, UCB, Janssen, Sistemix, TiGenics, Becton Dickinson, SDIX, Aldagen, Carefusion
February 14, 2012 : Big Pharma, dealtalk, Eli Lilly, J&J, Janssen, review, Roche, UCB
The news in the past week has been the lack of deal news. The past week has been very quiet on the dealmaking front, with very little of significance in terms of deals from bigpharma or deals with a high headline value more »
Points of view
Dealmakers weekly review – February 20 2012 – Biogen Idec, Stromedix, Tetraphase, BioGaia, Nexmed, Swedish Orphan Biovitrum
February 21, 2012
Partnering was up on the previous week in terms of number of deals, but no deals of financial significance were announced. Partnering in terms of big headline deals seems to have taken breather for the past few weeks. more »
Biogen Idec buys Stromedix to reacquire STX-100
February 15, 2012
Biogen Idec has acquired a venture backed US company in a deal which promises up to $487.5 million but only costs $75 million upfront more »
Dealmakers weekly review – February 13 2012 – Eli Lilly, Roche, UCB, Janssen, Sistemix, TiGenics, Becton Dickinson, SDIX, Aldagen, Carefusion
February 14, 2012
The news in the past week has been the lack of deal news. The past week has been very quiet on the dealmaking front, with very little of significance in terms of deals from bigpharma or deals with a high headline value more »
Glossary
Top 50 Pharma
July 1, 2011
Two-step merger
April 5, 2011
Second-step merger
April 5, 2011
Warranties
April 3, 2011
Valuation methods
April 3, 2011
